PRESCRIBE BY BRAND NAME TO ENSURE PATIENT CONTINUITY
Numerous national guidelines recommend that all biological medicines, including biosimilar medicines, should be prescribed by brand name[50-56].
The MHRA has confirmed that brand name prescribing for biological products is good practice. This ensures automatic substitution of a biosimilar product does not occur when dispensed and supports ongoing pharmacovigilance of products.
Guidance from NHS England states that automatic substitution is not permitted for biological medicines, including biosimilars.
As biosimilar medicines often use the same INN as their reference product, an important way to ensure substitution does not take place is through brand name prescribing.
PRESCRIPTIONS FOR ENOXAPARIN DISPENSED IN RETAIL
In 2018, only 52% of enoxaparin prescriptions dispensed in retail specified a brand. As a result, nearly half of patients prescribed enoxaparin may have received a different product and device to the one they were trained to use.
To review guidance from the relevant bodies concerning the prescription of biologics, please visit the links below. The references included above can be found on the “References” page located here.